Lonza teams up with Bio*One Capital
The building of the plant will include four mammalian bioreactor trains each with a flexible capacity of 1’000 up to 20'000 litres and inclusive of the respective purification units.
The building of the plant will include four mammalian bioreactor trains each with a flexible capacity of 1’000 up to 20'000 litres and inclusive of the respective purification units.
With this project Lonza further strengthens its leading position as a global custom manufacturer of biopharmaceuticals entering the fast growing Asian market.
The project is a further investment of Bio*One Capital in biopharmaceutical manufacturing.
It capitalizes on Singapore's existing strengths in process development and clinical manufacturing of biopharmaceuticals as well as the country's reputable capabilities in GMP manufacturing of bulk actives for global pharmaceutical companies.
The plant will be realized in two phases. Construction of the plant shell in the first phase will commence at end 2005. The final build-out of the plant will be completed within 24 months of the completion of the plant shell in line with customer commitments.
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
